CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.
September 14th 2023
Blenrep improves durability and provides meaningful response rates to patients with relapsed/refractory multiple myeloma, researchers found.
September 11th 2023
September 8th 2023
FDA Approval of Elrexfio Represents ‘a Very Hopeful Time’ for Heavily Pretreated Multiple Myeloma
August 28th 2023Elrexfio has been shown to provide patients with relapsed/refractory multiple myeloma who previously received four or more lines of therapy with a response that may last at least 15 months, an expert explained.
FDA Approves Elrexfio for Heavily Pretreated Relapsed/Refractory Multiple Myeloma
August 14th 2023The Food and Drug Administration granted accelerated approval for Elrexfio for the treatment of patients with relapsed or refractory multiple myeloma who previously received at least four lines of therapy.